Saltar al contenido
Merck

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Bioorganic & medicinal chemistry letters (2009-08-04)
Min Zhong, Minna Bui, Wang Shen, Subramanian Baskaran, Darin A Allen, Robert A Elling, W Michael Flanagan, Amy D Fung, Emily J Hanan, Shannon O Harris, Stacey A Heumann, Ute Hoch, Sheryl N Ivy, Jeffrey W Jacobs, Stuart Lam, Heman Lee, Robert S McDowell, Johan D Oslob, Hans E Purkey, Michael J Romanowski, Jeffrey A Silverman, Bradley T Tangonan, Pietro Taverna, Wenjin Yang, Josh C Yoburn, Chul H Yu, Kristin M Zimmerman, Tom O'Brien, Willard Lew
RESUMEN

This Letter describes the discovery and key structure-activity relationship (SAR) of a series of 2-aminobenzimidazoles as potent Aurora kinase inhibitors. 2-Aminobenzimidazole serves as a bioisostere of the biaryl urea residue of SNS-314 (1c), which is a potent Aurora kinase inhibitor and entered clinical testing in patients with solid tumors. Compared to SNS-314, this series of compounds offers better aqueous solubility while retaining comparable in vitro potency in biochemical and cell-based assays; in particular, 6m has also demonstrated a comparable mouse iv PK profile to SNS-314.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
2-Aminobenzimidazole, 97%